Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Alfimeprase · 5 trials · 6 indications
| Name | Type | Description |
|---|---|---|
| Alfimeprase | DRUG | single-dose of alfimeprase, 10 mg.administered intracatheter to an occluded CVAD |
Inclusion Criteria: * Must give written informed consent * Ages 18 or older * Unable to withdraw at least 3 mL of blood from a central venous access device * Hemodynamically stable * Available for follow-up assessments Exclusion Criteria: * Inability to infuse at least 2 mL of saline through the ...
Alfimeprase is an investigational small molecule being developed for cardiovascular conditions, specifically for arterial occlusive diseases, thrombosis, and occlusion of indwelling catheters. It is designed to clear thrombosed vascular access devices and treat acute peripheral arterial occlusion. The drug is currently in clinical development and has not been approved by the FDA.
Alfimeprase is being developed by Oruka Therapeutics, Inc., a biopharmaceutical company traded on the stock exchange under the ticker symbol ORKA. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with catheter occlusion and peripheral arterial occlusion.
Alfimeprase is in Phase 3 clinical development. The drug has completed Phase 2 and Phase 3 trials for conditions such as occluded catheters and acute peripheral arterial occlusion. It remains an investigational agent and has not received FDA approval for any indication.
Alfimeprase has been studied in several completed clinical trials, including NCT00073515 for thrombosed vascular access devices, NCT00073554 for acute peripheral arterial occlusion, NCT00322270 for occluded catheters, and NCT00346424 for occluded central catheters. These trials were conducted in the United States with adult participants.
Alfimeprase is a small molecule that acts as a fibrinolytic agent, meaning it works to break down blood clots. It is being investigated for its ability to clear thrombosed catheters and restore blood flow in arterial occlusive diseases. The drug targets the fibrin component of clots to dissolve them.
Alfimeprase is a distinct investigational drug developed by Oruka Therapeutics. It is not known to be the same as any other marketed medication. Its unique mechanism as a fibrinolytic agent differentiates it from other thrombolytic therapies, though it is still in clinical development.